A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?
Executive Summary
US FDA Commissioner Gottlieb suggests administrative action to prohibit drug rebates as a way to lower drug prices. His remarks may preview an upcoming proposal from President Trump and HHS Secretary Azar.
You may also be interested in...
‘Legacy’ Drugs And Former US FDA Commissioner Gottlieb’s Legacy
A surprise move to unwind FDA’s efforts to end the marketing of unapproved drugs is in keeping with the overall sense of the top-down intervention in the agency’s policies at the end of the Trump Administration. It is also an unfortunate consequence of the embrace of drug pricing as part of FDA’s mission.
Gottlieb Shifts From Regulatory To Reimbursement Focus In One Of First Post-Commissioner Appearances
CAR-T reimbursement is concern for former US FDA commissioner Scott Gottlieb in speech at the National Press Club.
Trump’s Drug Pricing ‘Dream Team’ And Prospects For Change
“We’re not looking for a lot of turnover. I think we have a team that works very well together,” HHS Deputy Secretary Eric Hargan said.